🇺🇸·11h agoIndustry
Bristol Myers Squibb and Hengrui Pharma Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
Publisher
B
Bristol-Myers Squibb News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on bristolmyers2016ir.q4web.com
Leave the platform to read the original full article on the publisher site.
Source: Bristol-Myers Squibb News
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News·4h ago
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
CPI (Healthcare Innovation)·6h ago
CPI appoints Hunada Nouss OBE as Non-Executive Director
Farmak (Ukraine)·8h ago
Farmak Launches “A Pill for Everything” Series on Responsible Medication Use
Roche Newsroom·9h ago